227029-22-3

Upstream product

• 106-49-0 p-toluidine 
• 1164-72-3 1-benzyl-4-(p-tolylamino)piperidine-4-carboxamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 972-19-0 1-benzyl-4-(p-tolylamino)piperidine-4-carbonitrile 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 976-95-4 8-benzyl-1-(p-tolyl)-1,3,8-triazaspiro[4.5]decan-4-one 
• 1026804-92-1 3-Methoxycarbonylmethyl-4-oxo-1-p-tolyl-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 180386-36-1 3-Carboxymethyl-4-oxo-1-p-tolyl-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 1026229-14-0 4-Oxo-1-p-tolyl-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction

Recent cardiology research studies have reported the role, function, and structure of the mitochondrial permeability transition pore (mPTP) and have shown that its opening plays a key role in the progression of myocardial cell death secondary to reperfusion. In this manuscript, we validated a new pharmacological approach as an adjunct to reperfusion in myocardial infarction (MI) treatment and describe the discovery, optimization, and structure-activity relationship (SAR) studies of the first small-molecule mPTP opening inhibitors based on a 1,3,8-triazaspiro[4.5]decane scaffold that targets the c subunit of the F1/FO-ATP synthase complex. We identified three potential compounds with good mPTP inhibitory activity and beneficial effects in a model of MI, including a decreased apoptotic rate in the whole heart and overall improvement of cardiac function upon administration during reperfusion. The selected compounds did not show off-target effects at the cellular and mitochondrial levels. Moreover, the compounds preserved the mitochondrial ATP content despite interacting with the ATP synthase complex.

1,3,8,-triaza spiro (4,5)decan-4-on derivatives

The present invention relates to compounds of formula I and pharmaceutically acceptable acid addition salts thereof.

Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system

A series of pseudopeptides containing alkyl-, cycloalkyl-, aryl-, and aralkyl-substituted 1,3,8-triazaspiro[4.5]decan-4-one-3-acetic acids as amino acid surrogates to replace the Pro2-Pro3-Gly4-Phe5 section of the peptide bradykinin B2 receptor antagonist [Pro3, Phe5]HOE 140 (D-Arg0-Arg1- Pro2-Pro3-Gly4-Phe5-Ser6-D-Tic7-Oic8-Arg9) were prepared. These psuedopeptides were examined in vitro for their B2 receptor affinities as well as for their ability to block bradykinin mediated actions in vivo. Two compounds in particular, NPC 18521 (I) and NPC 18688 (V) were quite potent in these latter assays, indicating that a significant portion of this prototypical second generation decapeptide antagonist can be replaced with a more compact nonpeptide molecule.